J. Safra Asset Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

J. Safra Asset Management’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-51	Closed	-$366	–	650
2025 Q3	$366	Hold	51	–	–	﹤0.01%	468
2025 Q2	$2.41K	Hold	51	–	–	﹤0.01%	345
2025 Q1	$1.99K	Buy	51 +43	+538%	+$1.85K	﹤0.01%	326
2024 Q4	$424	Hold	8	–	–	﹤0.01%	326
2024 Q3	$395	Buy	+8	New	+$375	﹤0.01%	289

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

J. Safra Asset Management's MLTX Position: Q4 2025 in Review

J. Safra Asset Management sold out of MoonLake Immunotherapeutics (MLTX) in Q4 2025, closing a stake of 51 shares — an estimated $366 sold.

J. Safra Asset Management first reported a position in MLTX in Q3 2024 and held it in 5 quarters. The position peaked at $2.41K in Q2 2025. 130 funds tracked by Wall St. Rank hold MLTX as of Q4 2025.

J. Safra Asset Management reported no remaining MoonLake Immunotherapeutics position as of Q4 2025 after selling out during the quarter.
J. Safra Asset Management sold 51 MoonLake Immunotherapeutics shares in Q4 2025, an estimated $366.
J. Safra Asset Management first reported a position in MoonLake Immunotherapeutics in Q3 2024 and held it in 5 quarters.
J. Safra Asset Management's MoonLake Immunotherapeutics position peaked at $2.41K in Q2 2025.
130 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q4 2025.

Based on J. Safra Asset Management's 13F filing for Q4 2025, filed 11 Feb 2026.